Everett E. Vokes
#69,621
Most Influential Person Now
American oncologist
Everett E. Vokes's AcademicInfluence.com Rankings
Everett E. Vokesphilosophy Degrees
Philosophy
#3690
World Rank
#5911
Historical Rank
Logic
#1334
World Rank
#2057
Historical Rank
Download Badge
Philosophy
Everett E. Vokes's Degrees
- Doctorate Medicine University of Chicago
- PhD Biochemistry University of Chicago
Why Is Everett E. Vokes Influential?
(Suggest an Edit or Addition)According to Wikipedia, Everett E. Vokes is an American oncologist. He is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medical Center. In this role, he pioneered the combination radiation and chemotherapy as first-line treatment for head and neck cancer.
Everett E. Vokes's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2015) (7370)
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. (2015) (6804)
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. (2016) (1900)
- Head and Neck Cancer (1993) (1386)
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens (2000) (1254)
- Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. (2004) (960)
- Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. (2008) (838)
- Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. (2004) (809)
- UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity (2002) (707)
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). (2017) (640)
- Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. (2008) (626)
- Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. (2003) (614)
- Recommended guidelines for the treatment of cancer treatment-induced diarrhea. (2004) (546)
- Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. (1994) (520)
- The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy‐head and neck scale: A study of utility and validity (1996) (503)
- Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas (2014) (499)
- Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. (2001) (484)
- Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. (2018) (477)
- Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. (2000) (475)
- Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. (2005) (473)
- Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. (2007) (420)
- Predictors of competing mortality in advanced head and neck cancer. (2010) (414)
- Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. (2014) (402)
- The concurrent chemoradiation paradigm—general principles (2007) (367)
- Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. (2002) (367)
- Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases (2018) (363)
- Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. (1990) (351)
- Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. (2004) (318)
- PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2016) (317)
- Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. (2005) (313)
- Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes (2014) (299)
- Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. (2009) (298)
- Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. (2001) (294)
- Expression and mutational analysis of MET in human solid cancers (2008) (287)
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. (2017) (276)
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. (2022) (276)
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. (2009) (268)
- The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. (2009) (255)
- Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. (2005) (253)
- The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. (2001) (253)
- Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. (2010) (247)
- p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. (1993) (242)
- Stereotactic body radiotherapy for multisite extracranial oligometastases (2012) (242)
- Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (2005) (237)
- Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. (2003) (235)
- Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. (2000) (231)
- The expanding role of systemic therapy in head and neck cancer. (2004) (230)
- Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. (1999) (228)
- The chemoradiation paradigm in head and neck cancer (2007) (219)
- Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. (2008) (218)
- Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. (1992) (214)
- Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. (2006) (213)
- Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. (2000) (212)
- Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review. (2003) (211)
- Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. (2007) (208)
- Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. (2012) (205)
- Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 (2015) (199)
- Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). (2018) (195)
- Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. (2008) (194)
- Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. (1994) (194)
- How Do head and neck cancer patients prioritize treatment outcomes before initiating treatment? (2000) (189)
- Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. (1997) (185)
- Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. (2003) (185)
- Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. (2006) (181)
- Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer (2021) (180)
- Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. (1997) (179)
- The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. (2000) (178)
- Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. (2010) (178)
- Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. (2006) (174)
- Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. (2004) (174)
- Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. (1996) (172)
- Treatment of hairy cell leukemia with recombinant alpha 2 interferon. (1985) (171)
- Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. (2008) (171)
- The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC (2017) (170)
- Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer (2009) (169)
- Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. (2011) (167)
- Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. (2009) (164)
- Competing Causes of Death and Second Primary Tumors in Patients with Locoregionally Advanced Head and Neck Cancer Treated with Chemoradiotherapy (2004) (163)
- Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. (2001) (162)
- Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. (2004) (161)
- Swallowing function in patients with head and neck cancer prior to treatment. (2000) (161)
- Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. (2008) (158)
- Recommended guidelines for the treatment of chemotherapy-induced diarrhea. (1998) (157)
- Phase 2 study of sunitinib in refractory thyroid cancer (2008) (156)
- Lung cancer (2000) (155)
- Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. (2008) (151)
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. (2008) (151)
- A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. (2002) (149)
- Phase I study of docetaxel with concomitant thoracic radiation therapy. (1998) (149)
- Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. (2000) (149)
- Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation (2006) (146)
- An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. (2003) (146)
- Neck dissection in the combined‐modality therapy of patients with locoregionally advanced head and neck cancer (2004) (146)
- Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). (2015) (143)
- Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR (2005) (142)
- DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). (2012) (140)
- Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. (2012) (136)
- Is patient travel distance associated with survival on phase II clinical trials in oncology? (2004) (136)
- Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. (2004) (135)
- Distribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human Sep15 gene. (2001) (135)
- Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial (2010) (133)
- Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. (2005) (132)
- MET as a target for treatment of chest tumors. (2009) (131)
- Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. (1996) (130)
- Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2006) (126)
- Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time (2004) (126)
- Lung cancer—a fractal viewpoint (2015) (126)
- Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). (2015) (126)
- Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. (1989) (121)
- Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. (2008) (120)
- Sex-associated differences in survival of patients undergoing resection for lung cancer. (2000) (119)
- Bcl‐xL and Bcl‐2 expression in squamous cell carcinoma of the head and neck (1999) (117)
- A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307 (2010) (116)
- Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. (1995) (116)
- Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer (2008) (116)
- A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer (2006) (115)
- EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation* (2010) (110)
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group. (2016) (109)
- Phase II study of flavopiridol in patients with advanced colorectal cancer. (2003) (108)
- Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. (1998) (108)
- Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer (2007) (107)
- Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer (2012) (106)
- Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. (2004) (106)
- HPV-Associated Head and Neck Cancer. (2015) (106)
- Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. (2006) (106)
- A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (2012) (106)
- CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases (2010) (106)
- Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. (1990) (103)
- Somatic acquisition and signaling of TGFBR1*6A in cancer. (2005) (99)
- Review: 5-Fluorouracil cardiotoxicity: A critical review (1990) (97)
- Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. (1992) (96)
- Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use (2019) (95)
- Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM) (2007) (94)
- Combined modality therapy of head and neck cancer. (1994) (94)
- Aspiration in chemoradiated patients with head and neck cancer. (2007) (94)
- Chemoradiotherapy for locally advanced head and neck cancer. (2007) (94)
- Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium (2008) (93)
- A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC) (2005) (93)
- Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. (2003) (93)
- A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who participated in US National Cancer Institute cooperative group studies. (2018) (92)
- PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription (2009) (91)
- Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. (2000) (91)
- A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). (2006) (90)
- ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer (2015) (90)
- Chemotherapy of squamous cell carcinoma of head and neck: the future is now. (1996) (90)
- Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines (1989) (88)
- An Initial Report of a Radiation Dose-Escalation Trial in Patients with One to Five Sites of Metastatic Disease (2008) (88)
- Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium (2012) (87)
- Phase II study of sunitinib malate in head and neck squamous cell carcinoma (2010) (86)
- ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 (2016) (86)
- RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma (2011) (85)
- A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. (2010) (84)
- Prognostic Factors in Advanced Head and Neck Cancer Patients Undergoing Multimodality Therapy (1991) (84)
- A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non–Small Cell Lung or Esophageal Cancer (2007) (83)
- OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer (2019) (82)
- An exploration of the pretreatment coping strategies of patients with carcinoma of the head and neck (2002) (81)
- Chemoradiation for patients with advanced oral cavity cancer (2009) (81)
- Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. (2000) (81)
- Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. (2006) (80)
- Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial. (2004) (79)
- Second malignancies in hairy cell leukemia (1985) (79)
- Interferons and other cytokines in head and neck cancer (1995) (79)
- Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. (2011) (78)
- Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. (2011) (78)
- Prioritizing treatment outcomes: Head and neck cancer patients versus nonpatients (2004) (78)
- A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer (2004) (78)
- Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. (2016) (77)
- Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097) (2010) (76)
- Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. (2010) (76)
- Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. (1999) (75)
- Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. (1997) (74)
- Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). (2021) (74)
- New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. (2013) (74)
- Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. (2010) (73)
- Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. (2019) (72)
- Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. (2016) (72)
- Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. (2003) (72)
- Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. (1988) (71)
- Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. (2003) (71)
- Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. (1998) (71)
- Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. (2004) (70)
- Long-term survival of patients with localized diffuse histiocytic lymphoma. (1985) (70)
- Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing Radiation (2011) (70)
- Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. (1998) (70)
- Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. (2008) (70)
- Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. (1994) (69)
- Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. (1993) (69)
- Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. (1996) (69)
- Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation (2011) (68)
- Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer (2007) (68)
- 5-Fluorouracil cardiotoxicity: a critical review. (1990) (67)
- Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. (2010) (67)
- Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. (2005) (66)
- Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) (2010) (65)
- Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): A phase II trial of the University of Chicago Phase II Consortium (2007) (65)
- Performance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck cancer (1997) (65)
- Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. (2016) (65)
- Planned Post‐Chemoradiation Neck Dissection: Significance of Radiation Dose (2006) (64)
- Locally advanced non-small cell lung cancer: the past, present, and future. (2008) (64)
- Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). (2012) (63)
- CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. (2018) (63)
- Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. (2016) (62)
- Phase II trial of sunitinib in medullary thyroid cancer (MTC). (2010) (62)
- A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases (2006) (61)
- OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. (2019) (60)
- Chemotherapy in the management of squamous-cell carcinoma of the head and neck. (2001) (59)
- Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. (2003) (57)
- CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304 (2012) (57)
- Phase II Trial of the O6-Alkylguanine DNA Alkyltransferase Inhibitor O6-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced Melanoma (2005) (57)
- Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy. (1995) (57)
- Nasopharyngeal carcinoma (1997) (57)
- Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. (1998) (57)
- Human papillomavirus expression and p53 gene mutations in squamous cell carcinoma. (1997) (56)
- Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy. (1993) (56)
- Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial (2019) (56)
- CALGB Study 9431: A randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC) (2000) (55)
- The role of EGFR inhibition in the treatment of non-small cell lung cancer. (2009) (55)
- Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. (1996) (55)
- Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers (2005) (55)
- Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy (2009) (55)
- Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). (2017) (55)
- A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. (2011) (54)
- Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. (2014) (54)
- Irinogenetics: what is the right star? (2006) (54)
- CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC) (2007) (54)
- The EphB4 Receptor Tyrosine Kinase Promotes Lung Cancer Growth: A Potential Novel Therapeutic Target (2013) (54)
- Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. (2012) (54)
- Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. (2017) (53)
- Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report (2012) (53)
- Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. (2016) (52)
- Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution. (1991) (52)
- Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. (2003) (52)
- An update on North American randomized studies in non-small cell lung cancer. (1998) (51)
- A Phase II study of oxaliplatin in urothelial cancer. (2005) (51)
- CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2014) (51)
- Interactions of chemotherapy and radiation. (1993) (51)
- Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. (2008) (50)
- Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies (2011) (49)
- Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial. (2004) (49)
- Feasibility of Endobronchial Ultrasound‐guided Transbronchial Needle Aspiration Cytology Specimens for Next Generation Sequencing in Non–small‐cell Lung Cancer (2017) (49)
- Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. (2008) (49)
- A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. (2004) (49)
- A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). (2015) (48)
- PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predom (2009) (48)
- Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium (2012) (48)
- Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. (2008) (47)
- A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer (1989) (46)
- Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. (2006) (46)
- Induction chemotherapy for head and neck cancer: recent data. (2010) (45)
- A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG) (2015) (45)
- Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. (2009) (44)
- Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107). (2006) (44)
- Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial (2007) (44)
- Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. (1995) (44)
- Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. (2005) (44)
- A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. (2003) (44)
- Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC) - a Phase II Trial (2005) (44)
- The transfacial approach for combined anterior craniofacial tumor ablation. (1989) (43)
- Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor (2018) (43)
- Personalized treatment of lung cancer. (2011) (43)
- Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. (2013) (43)
- Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study. (1989) (42)
- A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602) (2010) (42)
- Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. (2011) (42)
- Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. (2012) (42)
- Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives. (2020) (42)
- A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited‐stage small cell lung cancer in elderly patients versus younger patients (2018) (42)
- A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. (2000) (42)
- Arsenic Trioxide in Patients With Adenocarcinoma of the Pancreas Refractory to Gemcitabine: A Phase II Trial of the University of Chicago Phase II Consortium (2008) (42)
- Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. (2009) (42)
- Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. (2009) (41)
- Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. (2007) (41)
- Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141 (2016) (41)
- Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies (2004) (41)
- Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G) (2005) (41)
- Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets). (2016) (40)
- Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. (2020) (40)
- Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. (2013) (39)
- A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734. (2007) (39)
- Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. (1995) (39)
- The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. (2000) (38)
- A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma (2006) (38)
- Chemoradiation for locally advanced, unresectable NSCLC. New standard of care, emerging strategies. (1999) (38)
- Optimal therapy for unresectable stage III non-small-cell lung cancer. (2005) (38)
- A Pooled Analysis of Limited-Stage Small-Cell Lung Cancer Patients Treated with Induction Chemotherapy Followed by Concurrent Platinum-Based Chemotherapy and 70 Gy Daily Radiotherapy: CALGB 30904 (2013) (38)
- Phase II Trial of Paclitaxel–Topotecan–Etoposide Followed by Consolidation Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer: CALGB 30002 (2007) (37)
- Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. (2018) (37)
- Phase I/II Trial of Gefitinib and Oxaliplatin in Patients With Advanced Colorectal Cancer (2005) (37)
- O-277 CALGB 9732: Final report of a randomized phase III intergroup trial of etoposide(VP-16) and cisplatin (DDP) with or without paclitaxel(TAX) and G-CSF in patients with extensive stage small cell lung cancer(ED-SCLC) (2003) (37)
- Locally advanced head and neck cancer (2001) (36)
- A phase 2 study of cetuximab in combination with docetaxel in chemotherapy‐refractory/resistant patients with advanced nonsmall cell lung cancer (2009) (36)
- P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy. (2016) (36)
- Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab (2015) (36)
- Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer (2015) (36)
- A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. (1998) (35)
- Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes (2008) (35)
- Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC) (2008) (34)
- Survival and Analysis of Failure Following Hydroxyurea, 5‐Fluorouracil and Concomitant Radiation Therapy in Poor Prognosis Head and Neck Cancer (1991) (34)
- Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics (2013) (34)
- Differential expression of RON in small and non–small cell lung cancers (2012) (34)
- A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium Trial (2012) (34)
- Head and neck cancer in 2010: Maximizing survival and minimizing toxicity (2011) (34)
- Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer. (2016) (34)
- A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. (2003) (33)
- A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. (2004) (33)
- Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing (1989) (33)
- Concurrent Chemoradiotherapy for Unresectable Stage III Non–Small Cell Lung Cancer (2005) (33)
- How I do it: Head and neck and plastic surgery: Surgical management of the head and neck cancer patient following concomitant multimodality therapy (1995) (33)
- Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307) (2007) (33)
- Chemoreirradiation for recurrent salivary gland malignancies. (2010) (33)
- Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer (2009) (33)
- Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. (2006) (33)
- Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients (2018) (33)
- A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer (1990) (33)
- 1043OTreatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes (2017) (32)
- Free-Flap Reconstruction in the Doubly Irradiated Patient Population (2008) (32)
- Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer. (1994) (32)
- Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. (2015) (31)
- Non-small-cell lung cancer: then and now. (2013) (31)
- CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer (2021) (31)
- OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC (2019) (31)
- Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer. (2001) (30)
- Cisplatin, 5‐fluorouracil, and high‐dose oral leucovorin for advanced head and neck cancer (1989) (30)
- Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. (2013) (30)
- Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. (2001) (30)
- Chemoradiation for patients with large‐volume laryngeal cancers (2012) (30)
- The patterns of failure in patients with pathological stage I and II diffuse histiocytic lymphoma treated with radiation therapy alone. (1989) (30)
- Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. (2011) (29)
- Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer (1998) (29)
- Concurrent chemoradiotherapy for head and neck cancer. (2004) (29)
- Cetuximab in cancers of the lung and head & neck. (2004) (29)
- Therapeutic options for laryngeal cancer. (2003) (29)
- The evolving role of systemic therapy in carcinoma of the lung. (1992) (29)
- Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and / or erbB 2 Expressing Adenoid Cystic Carcinoma and Non – Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands (2007) (28)
- Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma (2004) (28)
- Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. (1999) (28)
- Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer. (1989) (28)
- Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. (2000) (28)
- Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. (2006) (28)
- Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097) (2008) (28)
- Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. (2005) (28)
- Race and competing mortality in advanced head and neck cancer. (2014) (28)
- Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN). (2004) (27)
- Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma (2019) (27)
- A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers (2007) (27)
- Phase II Studies of Bryostatin-1 in Patients with Advanced Sarcoma and Advanced Head and Neck Cancer (2004) (27)
- Advancing current treatments for cancer. (1996) (27)
- Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). (2015) (26)
- Differences in clinical trial patient attributes and outcomes according to enrollment setting. (2010) (26)
- A phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC). (2006) (26)
- Evidence-based role of bevacizumab in non-small cell lung cancer. (2013) (26)
- A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck (2007) (26)
- Concomitant chemoradiotherapy with cisplatin, 5‐fluorouracil and hydroxyurea in poor‐prognosis head and neck cancer (1992) (26)
- Chemotherapy for non-small cell lung cancer. The continuing challenge. (1991) (26)
- Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use. (2017) (26)
- Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. (2016) (25)
- Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Organ Preservation of Locoregionally Advanced Oral Cavity Cancer (2011) (25)
- Serum immunoerythropoietin levels in patients with cancer receiving cisplatin‐based chemotherapy (1991) (25)
- Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience. (1991) (25)
- Maintenance Sunitinib following Initial Platinum‐Based Combination Chemotherapy in Advanced‐Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double‐Blind, Placebo‐Controlled Phase III Study—CALGB 30607 (Alliance) (2017) (25)
- Evaluation of neuropathy in patients on suramin treatment (1997) (25)
- The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. (1992) (25)
- Prognostic Significance of Mucin and p53 Expression in Stage IB Non-small Cell Lung Cancer: A Laboratory Companion Study to CALGB 9633 (2010) (25)
- A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer. (1998) (24)
- MET and phosphorylated MET as potential biomarkers in lung cancer. (2011) (24)
- 35‐year‐old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after α‐interferon therapy (1992) (24)
- A Phase II trial of suramin monthly × 3 for hormone‐refractory prostate carcinoma (2004) (24)
- Volumetric visualization of head and neck CT data for treatment planning. (1999) (24)
- Radiotherapy with concomitant chemotherapy for head and neck cancer. (1991) (24)
- The role of paclitaxel in the treatment of head and neck cancer. (1995) (24)
- A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407--Early evaluation of feasibility and toxicity (2008) (24)
- Mineralocorticoid insufficiency due to suramin therapy (1996) (24)
- Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. (1999) (24)
- Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation (2016) (24)
- Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer receiving anti-PD-1 therapy. (2018) (23)
- Chemotherapy for stage IV non-small cell lung cancer. (1990) (23)
- A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and (2011) (23)
- Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): A phase II trial of the University of Chicago, PMH, and California Phase II Consortia (2008) (23)
- Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer. (2012) (23)
- Updated results of a phase II trial integrating gefitinib (G) into concurrent chemoradiation (CRT) followed by G adjuvant therapy for locally advanced head and neck cancer (HNC) (2007) (22)
- Should non-small cell carcinoma of the lung be treated with chemotherapy? Pro: chemotherapy is for non-small cell lung cancer. (1995) (22)
- 72 Multicenter trial of docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): Confirmation of prolonged survival☆ (1997) (22)
- Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538. (2021) (22)
- Bevacizumab (B) plus erlotinib (E) for patients (pts) with recurrent ovarian (OC) and fallopian tube (FT) cancer: Preliminary results of a multi-center phase II trial. (2006) (22)
- A phase II study of Epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin’s lymphomas (2005) (22)
- A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma (2007) (22)
- A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. (2013) (22)
- Induction chemotherapy: to use or not to use? That is the question. (2009) (22)
- High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. (2006) (21)
- Phase II Study of Induction Cisplatin and Irinotecan Followed by Concurrent Carboplatin, Etoposide, and Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer, CALGB 30206 (2013) (21)
- A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis. (2006) (21)
- Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium (2005) (21)
- A Phase I Trial of the Oral Platinum Analogue JM216 with Concomitant Radiotherapy in Advanced Malignancies of the Chest (2004) (21)
- Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations. (2013) (21)
- Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity (2021) (21)
- Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck (1997) (21)
- A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (1998) (21)
- Angiogenesis inhibition in the treatment of lung cancer. (2006) (21)
- A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores (2007) (21)
- Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck (2004) (21)
- A Phase II Trial of 9-Aminocaptothecin (9-AC) as a 120-h Infusion in Patients with Non-Small Cell Lung Cancer (2004) (20)
- Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevazicumab (BFHX) in intermediate stage head and neck cancer (HNC) (2007) (20)
- Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy. (2017) (20)
- Phase II Trial of Temozolomide and Irinotecan as Second-Line Treatment for Advanced Non–small Cell Lung Cancer (2006) (20)
- 1301PDThree-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) (2017) (20)
- Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue (2010) (20)
- A Phase I Trial of Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study). (2021) (19)
- Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. (2002) (19)
- A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma (2020) (19)
- Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer. (2012) (19)
- Chemotherapy‐related hemolytic‐uremic syndrome after the treatment of head and neck cancer. A case report (1990) (19)
- Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. (2021) (19)
- Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. (2020) (19)
- 5‐Fluorouracil With Oral Leucovorin and Hydroxyurea and Concomitant Radiotherapy for Stage III Non‐Small Cell Lung Cancer (1990) (19)
- Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: a phase I study. (1996) (19)
- Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 (2008) (19)
- Abstract CT022: Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141 (2017) (19)
- A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer. (2015) (18)
- Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (2017) (18)
- Radiation therapy in head and neck cancer: indications and limitations. (1994) (18)
- A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma (2006) (18)
- Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay (2020) (18)
- Osteoradionecrosis of the jaws as a risk factor in radiotherapy: a report of an eight-year retrospective review. (1998) (18)
- Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. (1999) (18)
- Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer (2014) (18)
- Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). (2004) (18)
- Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every 2 Weeks With Pegfilgrastim and Darbepoetin Alfa With and Without the Chemoprotector BNP7787 in Patients With Advanced Non-small Cell Lung Cancer (CALGB 30303) (2008) (18)
- A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer (1991) (18)
- Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer. (1997) (18)
- A phase II study of ARQ 501 in patients with advanced squamous cell carcinoma of the head and neck (2007) (18)
- A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia. (1990) (18)
- Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting. (2003) (18)
- Adjuvant and neoadjuvant treatments for NSCLC. (2002) (18)
- Laboratory and clinical studies of biochemical modulation by hydroxyurea. (1992) (17)
- Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. (2008) (17)
- Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. (1992) (17)
- Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer (2005) (17)
- Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. (1999) (17)
- Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141 (2017) (17)
- Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. (2011) (17)
- Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) (2004) (17)
- Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma (1998) (17)
- Chemoradiation for Locally Advanced, Unresectable NSCLC (1999) (17)
- Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context (2010) (17)
- Cediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase II trial of The University of Chicago Phase II Consortium. (2011) (17)
- Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633. (2010) (17)
- Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer (2013) (17)
- Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. (2010) (17)
- Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL (2017) (17)
- Combined modality therapy of solid tumours (1997) (17)
- Combined-modality therapy of head and neck cancer. (1997) (17)
- The promise of biochemical modulation in combined modality therapy. (1994) (17)
- Measurable impact: multimodality therapy of head and neck cancer. (1993) (17)
- Competing roads to larynx preservation. (2013) (17)
- Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. (1992) (17)
- Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. (1998) (17)
- Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck cancer. (2014) (16)
- O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer (2013) (16)
- Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer. (1995) (16)
- Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC (2020) (16)
- Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma (2021) (16)
- Erratum: ERRATUM: OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer (Ann Oncol (2019) DOI: 10.1093/annonc/mdy522) (2019) (16)
- Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer. (2001) (16)
- Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST). (2011) (16)
- EGFR-directed treatments in SCCHN. (2013) (16)
- Key signaling pathways and targets in lung cancer therapy. (2007) (16)
- Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer. (1998) (16)
- ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC. (2020) (16)
- A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days (1999) (16)
- Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC). (2015) (15)
- Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. (2015) (15)
- Oncologic Therapies (2003) (15)
- Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC (2018) (15)
- Chemoradiotherapy (CRT) and gefitinib (G) in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial. (2006) (15)
- PL03.06 Lobar or Sub-lobar Resection for Peripheral Clinical Stage IA = 2 cm Non-small Cell Lung Cancer (NSCLC): Results From an International Randomized Phase III Trial (CALGB 140503 [Alliance]) (2022) (15)
- Molecular targets to overcome radioresistance. (1992) (15)
- Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer. (2009) (15)
- Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633. (2011) (15)
- Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) (2008) (15)
- Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B. (1992) (14)
- A phase I study of intermittent infusion cladribine in patients with solid tumors (1994) (14)
- DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer (2014) (14)
- Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: a long-term analysis. (1998) (14)
- Integrated Genomic Analysis Suggests MLL3 Is a Novel Candidate Susceptibility Gene for Familial Nasopharyngeal Carcinoma (2015) (14)
- Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status. (2019) (14)
- Anaplastic carcinoma of the thyroid. (1996) (14)
- Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. (2012) (14)
- Current treatments and promising investigations in a multidisciplinary setting. (2005) (13)
- O-308 A phase I trial of pemetrexed + chest radiotherapy in patients with advanced or metastatic non-small-cell lung cancer or esophageal cancer (2003) (13)
- Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer. (2011) (13)
- A phase I study of STEALTH cisplatin (SPI-77) and vinorelbine in patients with advanced non small-cell lung cancer. (2000) (13)
- Perspectives on combination chemotherapy with concomitant radiotherapy for poor-prognosis head and neck cancer. (1992) (13)
- Gemcitabine and radiation therapy for non-small cell lung cancer. (1998) (13)
- Effect of the addition of temsirolimus to cetuximab in cetuximab-resistant head and neck cancers: Results of the randomized PII MAESTRO study. (2014) (13)
- Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer (2014) (13)
- Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial. (2021) (13)
- A randomized study of inpatient versus outpatient continuous intravenous infusion chemotherapy: psychosocial aspects. (1989) (13)
- Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme. (1995) (13)
- Phase II study of oxaliplatin (O) and paclitaxel (T) in advanced Non-Small Cell Lung Cancer (NSCLC) (2000) (13)
- Cellular and molecular mechanisms of radioresistance. (1995) (13)
- Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. (2013) (13)
- Initial Pulmonary Toxicity Evaluation of Chemoradiotherapy (CRT) Utilizing 74 Gy 3-Dimensional (3-D) Thoracic Radiation in Stage III Non-Small Cell Lung Cancer (NSCLC): A Cancer and Leukemia Group B (CALGB) Randomized Phase II Trial (2005) (13)
- Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. (2012) (13)
- AHNS Series – Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines (2017) (13)
- P-403 Vatalanib in patients with previously untreated advanced malignant mesothelioma (MM): Preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107) (2005) (13)
- Non-small-cell lung cancer. Toward the next plateau. (1994) (13)
- Treatment of head and neck and esophageal xenografts employing Alimta and concurrent ionizing radiation. (2001) (12)
- A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer (2005) (12)
- Keratoacanthomas and skin neoplasms associated with suramin therapy. (1996) (12)
- Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Post-Treatment Functional Outcomes. (2020) (12)
- Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database (2011) (12)
- Role of systemic therapy in advanced non-small-cell lung cancer. (1990) (12)
- Phase II Trial of Aminocamptothecin (9-AC/DMA) in Patients with Advanced Squamous Cell Head and Neck Cancer (2000) (12)
- Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. (2013) (12)
- Sexual Functioning and Head and Neck Cancer (1998) (12)
- Combined modality therapy in non-small cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy. (1998) (12)
- Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism (2011) (12)
- Clinical studies in non-small cell lung cancer: the CALGB experience. (1998) (12)
- A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer. (2007) (12)
- Swallowing function following multispecialty organ preservation treatment of advanced head and neck-cancer. (1994) (12)
- Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction (2011) (12)
- pKDR/KDR ratio predicts response in a phase I/II pharmacodynamic study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC) (2007) (12)
- Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non–Small Cell Lung Cancer (2019) (12)
- 417OPhase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs) (2015) (12)
- A phase II trial of the epothilone B analog BMS-247550 in patients (pts) with hepatobiliary cancer (HBC): An updated analysis. (2006) (12)
- Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. (2010) (11)
- A Phase I Trial of Docetaxel Based Induction and Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer (2007) (11)
- AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC). (2020) (11)
- Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial (2004) (11)
- Concomitant Hydroxyurea, 5-Fluorouracil, and Radiation Therapy for Recurrent Head and Neck Cancer: Early Results (1988) (11)
- Protein kinase C beta in malignant pleural mesothelioma (2008) (11)
- Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863). (2009) (11)
- Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer. (2005) (11)
- A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer (2006) (11)
- O-238 The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years (2003) (11)
- Integration of vinorelbine into chemotherapy strategies for non-small-cell lung cancer. (1995) (11)
- Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive‐Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE) (2016) (11)
- A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 (2009) (11)
- 35-year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after alpha-interferon therapy. (1992) (11)
- Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance). (2019) (11)
- All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages (2021) (11)
- A phase I study of erlotinib in combination with chemoradiation (CRT) for unresectable, locally advanced non-small cell lung cancer (NSCLC) (2005) (11)
- Enhancing the therapeutic index of concomitant chemoradiotherapy for head and neck cancer. (1998) (10)
- Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer. (2001) (10)
- Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive-stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results. (2010) (10)
- A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer. (1998) (10)
- Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study (2021) (10)
- Management of Early Head and Neck Cancer in Elderly Patients. (2018) (10)
- Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling (2016) (10)
- Role of dental hardware in oral cavity squamous cell carcinoma in the low‐risk nonsmoker nondrinker population (2018) (10)
- A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study (2020) (10)
- Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. (1997) (10)
- Response to the Methylation Inhibitor Dihydro-5-azacytidine in Mesothelioma Is Not Associated with Methylation of p16INK4a: Results of Cancer and Leukemia Group B 159904 (2008) (10)
- Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203. (2006) (10)
- Flow cytometry in hairy cell leukemia before and during interferon alfa‐2b therapy (1987) (10)
- Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. (2008) (10)
- 236 Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (INDCT) followed by concomitant chemoradiotherapy (XRT) in stage IIIB non small cell lung cancer (NSCLC): Toxicity data (CALGB study 9431) (1997) (10)
- Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003) (2011) (10)
- Evaluation of Oncology Trial Results Reporting Over a 10-Year Period (2021) (10)
- Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN). (2017) (9)
- Optima: A phase II dose and volume de-escalation trial for high- and low-risk HPV+ oropharynx cancers. (2017) (9)
- 211 Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma: CALGB 30307 (2006) (9)
- Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: a preliminary report. (1994) (9)
- A pilot trial of G 3139 , a bcl-2 antisense oligonucleotide , and paclitaxel in patients with chemorefractory small-cell lung cancer (2002) (9)
- Radioresistant tumor cell lines derived from head and neck radiation failures (1989) (9)
- The Impact of Staging by Positron‐Emission Tomography on Overall Survival and Progression‐Free Survival in Patients With Locally Advanced NSCLC (2018) (9)
- Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): An ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial. (2014) (9)
- Implantable Venous Access Device: Use in Patients with Advanced Head and Neck Cancer (1988) (9)
- Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304 (2011) (9)
- C5-06: Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma (2007) (9)
- Results of Radiation Therapy Oncology Group 97-03—A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck: Long-term Results and Late Toxicities (2007) (9)
- Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups (2018) (9)
- Letters to the editor: 5-Fluorouracil cardiotoxicity: The risk of rechallenge (1991) (9)
- 5-fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study (2004) (9)
- Genomic profiling of kinase genes in head and neck squamous cell carcinomas to identify potentially targetable genetic aberrations in FGFR1/2, DDR2, EPHA2, and PIK3CA. (2013) (9)
- Long-term outcome of re-irradiation with concomitant chemotherapy for locally recurrent squamous cell carcinoma of the head and neck (2003) (9)
- Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: A phase II trial of the University of Chicago phase II consortium. (2011) (8)
- A pilot study of the pan‐class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer (2019) (8)
- Mechanism of acquired resistance to cetuximab in head and neck cancer. (2018) (8)
- Fluorouracil modulation in head and neck cancer. (1993) (8)
- CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM). (2010) (8)
- Multimodality determination of HPV status in head and neck cancers (HNC) and development of an HPV signature. (2013) (8)
- 5-fluorouracil plus radiation for head and neck cancer. (1995) (8)
- Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study. (1996) (8)
- Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC) (2008) (8)
- Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials (2017) (8)
- Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study (2004) (8)
- Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial. (2004) (8)
- O-183 A phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) (CT) with or without adjuvant radiation therapy (RT) for resected stage III non-small cell lung cancer (NSCLC): CALGB 9734 (2003) (8)
- A multi-center phase II study of arsenic trioxide (AT) in patients (Pts) with advanced pancreatic cancer (PC) refractory to gemcitabine (2004) (8)
- Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology (2022) (8)
- Chemotherapy in head and neck cancer (1992) (8)
- Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105. (2006) (8)
- Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. (2022) (8)
- Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial (2020) (8)
- Hairy‐cell leukemia associated with Hodgkin's disease: A case report (1985) (8)
- CALGB 30103: A randomized phase II study of carboplatin and etoposide (CE) with or without G3139 in patients with extensive stage small cell lung cancer (ES-SCLC) (2005) (8)
- Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. (2021) (8)
- Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer (2014) (8)
- CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). (2012) (8)
- Recent advances in radiation therapy for head and neck cancer. (1991) (8)
- Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): A randomized phase II trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291. (2004) (7)
- Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis. (2013) (7)
- CALGB 30206: Phase II study of induction cisplatin (P) and irinotecan (I) followed by combination carboplatin (C), etoposide (E), and thoracic radiotherapy for limited stage small cell lung cancer (2007) (7)
- Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. (2015) (7)
- OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. (2019) (7)
- 3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs) (2015) (7)
- Recombinant human interleukin 4 (IL-4) sch 39400 in non-small cell lung cancer (NSCLC): Results of a phase II investigation (1994) (7)
- Randomized phase I trial to evaluate Concurrent or Sequential Ipilimumab, Nivolumab, and stereotactic body Radiotherapy in patients with stage IV non-small cell lung cancer (COSINR Study). (2020) (7)
- CHART for non-small-cell lung cancer-promises and limitations (1997) (7)
- Phase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC and performance status (PS) 2--CALGB 30402 (2007) (7)
- Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement (2005) (7)
- PD-L1 Immunohistochemistry Assay Comparison Studies in Non-Small Cell Lung Cancer: Characterization of the 73-10 Assay. (2020) (7)
- Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. (2004) (7)
- Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. (2013) (7)
- AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC). (2021) (7)
- Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study (2004) (7)
- ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer. (2015) (7)
- Elimination pathways of [14C]losoxantrone in four cancer patients. (2001) (7)
- Molecular Inhibition of mTOR with Temsirolimus (TORISEL™, CCI-779) Is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium. (2006) (7)
- Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus (1996) (7)
- Association of a baseline neutrophil-to-lymphocyte ratio (NLR) with progression-free and overall survival in head and neck cancer patients receiving anti-PD-1 therapy. (2018) (6)
- Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy (2016) (6)
- Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? (2008) (6)
- Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538. (2021) (6)
- The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium (2010) (6)
- A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. (2006) (6)
- Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer. (1997) (6)
- Correction: CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases (2011) (6)
- Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC. (2018) (6)
- Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. (2014) (6)
- Phase I Study of Docetaxel and Concomitant Chest Radiation (1997) (6)
- A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer (2002) (6)
- A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients. (1991) (6)
- Long-term response to crisnatol mesylate in patients with glioma. (1997) (6)
- Sustained Oligoclonal T Cell Expansion Correlates with Durable Response to Immune Checkpoint Blockade in Lung Cancer (2017) (6)
- 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium (2004) (6)
- Chemotherapeutic and biologic radiation enhancement (1991) (6)
- A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2015) (6)
- Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors (2021) (6)
- Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis (2004) (6)
- Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma (2016) (6)
- Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of in vitro expanded populations in head and neck cancer (2017) (6)
- Clinical studies of docetaxel (Taxotere) and concomitant chest therapy. (1997) (6)
- Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. (2008) (6)
- Genomic profiling of a clinically annotated cohort of locoregionally advanced head and neck cancers (HNC) treated with definitive chemoradiotherapy. (2012) (6)
- Chemotherapy and integrated treatment approaches in head and neck cancer. (1991) (6)
- A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101. (2021) (6)
- Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: A phase II Illinois Cancer Council study (1989) (6)
- Use of systematic analysis of DNA repair pathways in head and neck cancer (HNC) to identify XPF as a novel predictor of induction response, and pMK2 relationship to chemoradiotherapy (2008) (6)
- A review of ifosfamide and vinorelbine in advanced non-small cell carcinoma of the lung. (1998) (6)
- Radiation Therapy Oncology Group. Research Plan 2002-2006. Head and Neck Cancer Committee. (2001) (6)
- Ifosfamide and vinorelbine in advanced non-small cell lung cancer (1997) (5)
- The Functional Assessment of Cancer Therapy-Head & Neck Scale (FACT H&N, 4th version). (1996) (5)
- OPTIMA—A Phase 2 Trial of Induction Chemotherapy Response-Stratified Radiation Therapy Dose and Volume De-escalation for HPV+ Oropharyngeal Cancer: Efficacy, Toxicity, and HPV Subtype Analysis (2018) (5)
- Markers of bone metabolism predict survival in hormone refractory prostate cancer (HRPC): Results from a randomized California Cancer Consortium & University of Chicago trial (2005) (5)
- Veliparib (Vel) in combination with chemoradiotherapy (CRT) of carboplatin/paclitaxel (C/P) plus radiation in patients (pts) with stage III non-small cell lung cancer (NSCLC) (M14-360/AFT-07). (2019) (5)
- Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung Cancer (2008) (5)
- Abstract CT157: Treatment beyond progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in the phase 3 Checkmate 141 study (2017) (5)
- Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer. (2003) (5)
- Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. (1989) (5)
- Chemoradiotherapy for stage III non-small cell lung cancer (1997) (5)
- Heat shock proteins in normal and leukemic blood cells. (1989) (5)
- A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest (1995) (5)
- Head and neck cancer committee (2001) (5)
- ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). (2015) (5)
- Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. (1998) (5)
- 5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis. (1993) (5)
- 24 : Definitive Chemoradiotherapy for T4 Laryngeal Squamous Cell Carcinoma (2006) (5)
- Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment (2022) (5)
- Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC). (2019) (5)
- Abstract CT238: Phase III randomized, placebo controlled trial of COX-2 inhibition in addition to standard chemotherapy for advanced non-small cell lung cancer (NSCLC):CALGB 30801 (Alliance) (2014) (5)
- Safety and Efficacy of a Randomized Phase I Trial to Evaluate Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-small Cell Lung Cancer (COSINR Study) (2020) (5)
- Phase II trial of paclitaxel-topotecan-etoposide (PTE) followed by consolidation chemoradiotherapy for limited stage small cell lung cancer (LS-SCLC): CALGB 30002 (2005) (5)
- Low risk HPV associated oropharyngeal squamous cell carcinoma treated with induction chemoimmunotherapy followed by TORS or radiotherapy (2020) (5)
- Chemoprevention in head and neck cancer. (2001) (5)
- Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains? (2019) (5)
- A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent/metastatic head and neck cancer. (2017) (5)
- Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin (1996) (5)
- Current strategies for locoregionally advanced unresectable non-small cell lung cancer. (1999) (4)
- Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck (1995) (4)
- Induction chemotherapy, surgery and concomitant chemoradiotherapy for carcinoma of the esophagus (1994) (4)
- Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC). (2020) (4)
- A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors (1999) (4)
- A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer (HNC) (2008) (4)
- Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma (2012) (4)
- Clinical prognostic model for older patients with advanced non-small cell lung cancer. (2019) (4)
- A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101. (2018) (4)
- Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141 (2022) (4)
- A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC (2021) (4)
- Response-adapted volume de-escalation (RAVD) of radiotherapy (RT) using induction chemotherapy (IC) in locally advanced head and neck squamous cell cancer (LA-HNSCC). (2015) (4)
- Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer (2004) (4)
- Suramin: is adaptive control necessary? (1992) (4)
- Randomized phase 2 trial of cediranib alone or cediranib plus lenalidomide in iodine 131-refractory differentiated thyroid cancer (DTC): A University of Chicago Phase 2 Consortium trial. (2016) (4)
- Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte‐macrophage colony stimulating factor support (1996) (4)
- [Advances in the treatment of head and neck tumors. 2. Radiochemotherapy]. (1995) (4)
- A phase II study of carboplatin, etoposide and exisulind in patients with extensive stage small cell lung cancer: CALGB 30104 (2005) (4)
- Correlation of constitutive PD-1 resistance in HNC with GM-CSF expression and presence of myeloid derived suppressor cells (MDSCs). (2017) (4)
- Adjuvant and Neoadjuvant Chemotherapy for Early-Stage Nonsmall Cell Lung Cancer (2018) (4)
- Docetaxel and Exisulind in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients: A Multicenter, Phase II Clinical Trial (2007) (4)
- Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. (2009) (4)
- A phase II study of dasatanib (BMS 354825) in recurrent or metastatic ckit-expressing adenoid cystic (ACC) and non-ACC malignant salivary glands tumors (MSGT). (2013) (4)
- Ultra-sensitive detection and quantification of HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial. (2021) (4)
- Abstract #LB-119: Expression and Function of PAX5 Transcription Factor and Regulation of c-MET in SCLC -Potential for Novel Biomarkers and Therapeutics (2009) (4)
- Heuristic value-based framework for lung cancer decision-making (2018) (4)
- Timing and sequencing of chemoradiotherapy. (1995) (4)
- Patterns of CD8+ T-cell infiltration and immune escape mechanisms in head and neck cancer. (2015) (4)
- A randomized phase II study of 5-fluorouracil , hydroxyurea , and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil , hydroxyurea , and twice-daily radiotherapy for intermediate-stage and T 4 N 0-1 head and neck cancers (2011) (4)
- P3.02c-058 In-Depth Molecular Characterization of T Cell Clonal Expansion Induced by Anti-PD1 Therapy in NSCLC: Topic: IT Biomarkers (2017) (4)
- 359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results (2020) (4)
- Therapy for locoregionally advanced head and neck cancer (1997) (4)
- EGFR-based bioradiotherapy in SCCHN. (2015) (4)
- Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. (2015) (4)
- PD-48 Pemetrexed-based concurrent chemoradiotherapy (CRT)for locally advanced or metastatic non-small cell lung or esophageal cancer: A phase I dose-escalating study (2005) (4)
- Chemotherapy and combined modality therapy in head and neck cancer. (1993) (3)
- Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies. (1996) (3)
- MET/PKCß expression correlate with metastasis and inhibition is synergistic in lung cancer (2009) (3)
- Paclitaxel and ifosfamide: a multicenter phase I study in advanced non-small cell lung cancer. (1995) (3)
- Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141 (2018) (3)
- Quality of life (QL) and performance outcome in survivors of concomitant chemoradiotherapy protocols for head and neck cancer (HNC) (Meeting abstract). (1997) (3)
- Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on the experimental thoracic radiotherapy (TRT) arms of CALGB 30610 (Alliance) / RTOG 0538 (2019) (3)
- Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer. (1997) (3)
- P1.01-133 Randomized Open-Label Study of Bintrafusp Alfa (M7824) vs Pembrolizumab in Patients with PD-L1 Expressing Advanced 1L NSCLC (2019) (3)
- Activity of Temsirolimus Added to Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head-and-Neck Cancer: Results of the Randomized Phase 2 Maestro-HN Study (2014) (3)
- High-accuracy HPV testing versus p16 IHC using multiple clinically relevant outcomes: The University of Chicago Experience. (2018) (3)
- A phase I study of cisplatin, tirapazamine and accelerated re-irradiation in unresectable recurrent head and neck cancer (2004) (3)
- OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC (2021) (3)
- Cooperative group research endeavors in small-cell lung cancer: current and future directions. (2009) (3)
- Concomitant 5-FU, hydroxyurea and cisplatin with external beam radiation therapy for locally advanced pancreatic cancer. (1997) (3)
- Updated analysis of a phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) (CT) with or without adjuvant radiation therapy (RT) for resected stage III non-small cell lung cancer (NSCLC) CALGB 9734 (2005) (3)
- 147 Quality of life and performance in patients undergoing the larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer (1999) (3)
- Sequential evaluation of reduced radiotherapy doses in a phase II trial of induction chemotherapy (IndCT) followed by concomitant chemoradiotherapy (CTX) for advanced head and neck cancer (HNC). (2006) (3)
- Treatment of advanced head and neck cancer with induction chemotherapy followed by chemoradiotherapy with reduced radiation dose. (2004) (3)
- Validation of two biologically distinct HPV-associated head and neck cancer subtypes and correlation with E5 expression. (2014) (3)
- Sequential combined modality therapy for stage III non-small cell lung cancer. (1990) (3)
- Concomitant chemoradiotherapy for non-small cell lung cancer. (1994) (3)
- Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study (2007) (3)
- Searching for a standard. (2002) (3)
- Ifosfamide-based chemotherapy for non-small cell lung cancer: phase I/II studies at the University of Chicago. (1996) (3)
- Dose and volume de-escalation for HPV-associated oropharyngeal cancer: Long-term follow-up of the OPTIMA trial. (2020) (3)
- Dose intensification--a phase I study of ifosfamide with vinorelbine (Navelbine): rationale and study design in advanced non-small cell lung cancer. (1995) (3)
- P2.18-01 A Multicenter, Double-Blind, Randomized, Controlled Study of Bintrafusp Alfa (M7824) in Unresectable Stage III NSCLC (2019) (3)
- Reply to With regard to “Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer”, by Oh et al. (Ann Oncol 2003; 14: 564–569) (2004) (3)
- Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer: Toxicity and outcome results. (2004) (3)
- Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe (2017) (3)
- Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center study. (1995) (3)
- Phase II trial of etoposide and doxorubicin in advanced head and neck cancer. (1990) (3)
- Multimodality therapy for esophageal cancer: an emerging role. (1998) (3)
- A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design. (1994) (3)
- Molecular characterization of immune exclusion in small-cell lung cancer. (2016) (3)
- Switch Maintenance With Sunitinib (S) in Advanced Non-Small Cell Lung Cancer (NSCLC): An Alliance (CALGB 30607), Randomized, Placebo-Controlled Phase 3 Trial (2014) (3)
- A randomized, double-blind phase II study of pembrolizumab versus placebo in patients with head and neck cancers at high risk for recurrence or low-volume residual disease: The PATHWay Study. (2017) (3)
- Correlation of body mass index with toxicity and survival in locoregionally advanced head and neck cancer patients treated with induction chemotherapy and concurrent chemoradiotherapy. (2009) (3)
- Introduction: head and neck cancer. (2008) (3)
- Chemotherapy, biologics, and chemoprevention as systemic therapies for head and neck cancer. (1994) (3)
- Response-Adapted Volume Deescalation (RAVD) in Locally Advanced Head and Neck Squamous Cell Cancer (LA-HNSCC): Toxicity and Quality of Life (QOL) Analyses (2015) (2)
- Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose. (1996) (2)
- Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours (2002) (2)
- Sustained oligoclonal T cell expansion correlates with durable response to anti-PD1 therapy. (2017) (2)
- Combination MET inhibition and Topoisomerase I inhibition block cell growth of Small Cell Lung Cancer (2013) (2)
- Etoposide combined with interferon alfa‐2b: Novel exploitation of established etoposide pharmacokinetics and pharmacodynamics (1996) (2)
- A phase I study of induction chemotherapy (CT) and concomitant chemoradiotherapy (CRT) with carboplatin (C), paclitaxel (P), and irinotecan (I) for stage III non-small cell lung cancer (NSCLC) (2004) (2)
- Twice-daily re-irradiation of recurrent and second primary head and neck cancer with gemcitabine, paclitaxel and fluorouracil chemoradiotherapy. (2004) (2)
- Predictors of pulmonary toxicity in limited-stage (LS) small cell lung cancer (SCLC) patients treated with concurrent chemotherapy (CTX) and high-dose (70 Gy) daily radiotherapy (RT): A pooled analysis of three CALGB studies. (2011) (2)
- MO01.29 Randomized, Open-Label Study of Bintrafusp Alfa vs. Pembrolizumab as First-Line (1L) Treatment in Patients with PD-L1–Expressing Advanced Non-Small Cell Lung Cancer (NSCLC) (2021) (2)
- Cardiac Gallium Uptake in Doxorubicin-lnduced Cardiotoxicity (1986) (2)
- Improving outcomes in the treatment of locally-advanced NSCLC with gemcitabine. (2005) (2)
- A pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. Cooperative Group Trials: comparing the outcomes of elderly to younger patients (pts) (2016) (2)
- Interim analysis of CALGB 150607: A pilot project to study the expression of MET and P53 in resected lung adenocarcinoma specimens. (2010) (2)
- Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer. (2003) (2)
- 88 Results of aggressive reirradiation with concomitant chemotherapy in recurrent unresectable head and neck cancer (HNC) (1996) (2)
- An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC). (2013) (2)
- Phase I study of dose-dense alternating doublets in advanced non-small-cell lung cancer. (2002) (2)
- The Cancer and Leukemia Group B Respiratory Committee (2006) (2)
- Baseline Urinary PGE-M Is a Prognostic and Predictive Marker for Cox-2 Inhibition in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC): CALGB 30801 (Alliance) (2014) (2)
- Mutations of the p53 tumor suppressor gene may predict radiotherapy failure in head and neck cancer patients (1992) (2)
- Oral Scientific SessionsA Phase 2 Dose and Volume De-escalation Trial for High- and Low-Risk HPV+ Oropharynx Cancer: Efficacy, Toxicity, and Dosimetric Analyses (2017) (2)
- Phase II trial pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated head and neck cancer patients (2008) (2)
- Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001). (2019) (2)
- A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). (2018) (2)
- A phase II study of pembrolizumab and docetaxel for aggressive RAI refractory thyroid carcinomas or salivary gland cancers: The iPRIME study. (2017) (2)
- Phase I and pharmacokinetic study of vatalanib plus capecitabine in patients with advanced cancer (2007) (2)
- Pharmacokinetics and Pharmacodynamics of 9-Aminocamptothecin Infused Over 72 Hours in Phase II Studies 1 (1999) (2)
- Effect of FGFR1 on epithelial-mesenchymal transition and EGFR resistance in HNC: A systems biology approach. (2014) (2)
- [Advances in the treatment of head and neck tumors. I. Chemotherapy]. (1995) (2)
- Phase I dose escalation study of tumor necrosis factor and radiation (1993) (2)
- Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer. (1996) (2)
- Neck dissection planning based on postchemoradiation computed tomography in patients with head and neck cancer. (2009) (2)
- Refining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC) (2008) (2)
- Concomitant chemoradiotherapy as investigational therapy for locoregionally advanced head and neck cancer. (1992) (2)
- PS02.23 CCDC6-RET Fusion as a Mechanism of Acquired EGFR Resistance: Topic: Medical Oncology (2017) (2)
- Harvey ras (HRAS) mutations in head and neck cancer (HNC) and dependence on PI3K signaling and resistance to EGFR inhibition. (2014) (2)
- Outcomes of Induction Chemotherapy and Concurrent Chemoradiation for Nasopharyngeal Carcinoma (2012) (2)
- CI-980 in Advanced Melanoma and Hormone Refractory Prostate Cancer (2000) (2)
- Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation Therapy for Locoregionally Advanced Head and Neck Cancer: HPV-negative Subset Analysis (2016) (2)
- High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. (2023) (2)
- Oral 5-FU alternatives for the treatment of head and neck cancer. (1998) (2)
- Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent and/or metastatic squamous cell carcinoma of the head and neck. (2011) (2)
- Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 (2008) (2)
- Pooled Analysis of Late Toxicity From 2 Randomized Phase 2 Trials of Induction Chemotherapy (IC) and Chemoradiation Therapy (CRT) for Locally Advanced Head and Neck Squamous Cell Cancer (LA-HNSCC) (2016) (2)
- Conservation Therapy in Patients with Head and Neck Carcinoma (1996) (2)
- Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study (2004) (1)
- An Interim Report Of CALGB 150607: Expression And Mutational Status Of c-MET, HGF, EGFR, KRAS, p53, c-CBL, And E-cadherin In Resected Lung Adenocarcinoma Specimens (2012) (1)
- CYFRA 21-1 (CYFRA) as a prognostic and predictive marker in advanced non-small cell lung cancer (NSCLC): CALGB 150304. (2009) (1)
- Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer (2014) (1)
- Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC). (2020) (1)
- A multi-center phase II study of arsenic trioxide (AT) in patients (Pts) with advanced pancreatic cancer (PC) refractory to gemcitabine. (2004) (1)
- Tolerability of veliparib (V) in combination with carboplatin (C)/paclitaxel (P): Based chemoradiotherapy (CRT) in subjects with stage III non-small cell lung cancer (NSCLC). (2017) (1)
- Concomitant chemoradiotherapy for solid tumors (1994) (1)
- A phase I study of cisplatin, tirapazamine and accelerated re-irradiation in unresectable recurrent head and neck cancer. (2004) (1)
- Phase I study of carboplatin and vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer (2000) (1)
- Head and Neck Tumors (2003) (1)
- Continuous Intravenous 5-Fluorouracil with Hydroxyurea and Concomitant Radiotherapy for Advanced Head and Neck Cancer (1991) (1)
- Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy (2018) (1)
- MA15.07 Molecular Determinants of Lack of Tumor Immune Infiltration in NSCLC (2017) (1)
- P3.04-003 Phase II Trial of Atezolizumab Before and After Definitive Chemoradiation for Patients with Unresectable Stage III NSCLC (2017) (1)
- Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer. (2001) (1)
- Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal SCC over two decades. (2014) (1)
- Lung Cancer (2015) (1)
- Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer (2019) (1)
- 69 Paclitaxel (TAX), ifosfamide (IFX), and vinorelbine (NVB) with G-CSF support in advanced non-small cell lung cancer (NSCLC): A phase I–II study (1997) (1)
- A phase I study of dose-dense “alternating doublets” chemotherapy with filgrastim (rhG-CSF) support in advanced non-small cell lung cancer (NSCLC) (2000) (1)
- Correlation of specific genetic aberrations and signaling pathways with T-cell inflamed phenotype (TCIP) in head and neck cancer and as novel candidate biomarkers for checkpoint blockade therapy. (2015) (1)
- Role of c-MET in lung cancer, malignant mesothelioma, and head and neck cancer. (2004) (1)
- Prognostic factors in early stage head and neck squamous cell carcinoma (HNSCC) patients in a prospective clinical trial (2004) (1)
- A Phase II Trial of Oral Trimethylcolchicinic Acid in Patients with Hormone Refractory Prostate Cancer (1999) (1)
- Response-Adapted Volume De-escalation (RAVD) in Locally Advanced Head and Neck Cancer: Efficacy and Human Papillomavirus–Positive Subgroup Analysis (2016) (1)
- Seeking improved outcome in the curative treatment of non-small-cell lung cancer. (2005) (1)
- Molecular correlates (EGFR status) and plasma VEGF levels associated with a phase II study of bevacizumab plus erlotinib (BE) for patients with recurrent ovarian cancer (OC) and fallopian tube (FT) cancer (2007) (1)
- Impact of Cardiac Dose on Cardiac Events and Survival in Unresectable Lung Cancer Patients. (2017) (1)
- Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer (2014) (1)
- Intensified and accelerated concomitant chemoradiotherapy and G-CSF for locally advanced head and neck cancer (1993) (1)
- Lymphatic vessel density is not associated with lymph node metastasis or survival in non-small cell lung carcinoma (NSCLC) (2007) (1)
- P3.03-036 Prognostic Model for Mesothelioma Based on Cancer and Leukemia Group B (CALGB) Trials (Alliance):Topic: Mesothelioma Clinical (2017) (1)
- Cancer of the Upper Gastrointestinal Tract (2002) (1)
- Reports of Oncological Societies (2014) (1)
- Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer. (2001) (1)
- Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801. (2009) (1)
- Prolonging Life, but at What Price? (2019) (1)
- Molecular and Cellular Pathobiology Critical Role for the Receptor Tyrosine Kinase EPHB 4 in Esophageal Cancers (2013) (1)
- Locally advanced non-small cell lung cancer (2001) (1)
- Long-term experience with cisplatin-based induction chemotherapy and concomitant chemoradiotherapy in locally advanced head and neck cancer (HNC) (1993) (1)
- Efficacy and Safety of Single-Agent Axitinib (AG-013736; AG) in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC): A Phase II Trial (2007) (1)
- Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. (2021) (1)
- Phase II trial of O6-benzylguanine (O6BG) and BCNU in patients with advanced melanoma (2004) (1)
- MA 17.07 Veliparib in Combination with Paclitaxel/Carboplatin (P/C)-Based Chemoradiotherapy (CRT) in Patients with Stage III NSCLC (2017) (1)
- Neoadjuvant therapy for stage III non-small-cell lung cancer : a review (1992) (1)
- Combined modality therapy with radiation in NSCLC (1997) (1)
- A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. (2011) (1)
- Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer (2022) (1)
- MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer (2019) (1)
- Curative treatment for advanced head and neck cancer in the community: has the time come? (2002) (1)
- A randomized phase II trial of Interleukin-2 in combination with four different doses of bryostatin in patients with renal cell carcinoma. (2004) (1)
- Does Cetuximab Improve Control of Advanced Head and Neck Cancer? A Second Look at the Randomized Trial by Bonner, et al. (2007) (1)
- O-077 Gemcitabine/cisplatin plus bevacizumab or placebo in advanced malignant mesothelioma: A multi-center, double-blind placebo-controlled, randomized phase II trial (2005) (1)
- ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards. (2017) (1)
- Time-dose analysis of local control for advanced head and neck neoplasms treated with concomitant chemoradiotherapy on an alternate week schedule (1993) (1)
- Hypomagnesaemia and its management following treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs): Results from 3 randomized studies of necitumumab (NECI) plus chemotherapy in first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC) (2016) (1)
- PS01.05: Early and Persistent Oligoclonal T Cell Expansion Correlates with Durable Response to Anti‐PD1 Therapy in NSCLC: Topic: Medical Oncology (2016) (1)
- The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium. (2007) (1)
- O-038 Initial pulmonary toxicity evaluation of chemoradiotherapy (CRT) utilizing 74 Gy 3-dimensional (3-D) thoracic radiation in stage III non-small cell lung cancer (NSCLC): A Cancer and Leukemia Group B (CALGB) randomized phase II trial (2005) (1)
- 272 A phase I study of JM-216 with concomitant radiation therapy for patients (pts) with malignancies of the chest (1997) (1)
- The impact of induction chemotherapy on subsequent concurrent chemoradiotherapy (CRT) related side effects, function & quality of life (QOL) in head and neck cancer (HNC). (2004) (1)
- OA02.04 The Cost and the Benefit: Front-Line Immunotherapy for Non-Small Cell Lung Cancer: Topic: Medical Oncology (2017) (1)
- Medical oncology committee (2001) (1)
- D2-03: Erlotinib (E) as a single agent or intercalated with carboplatin and paclitaxel (ECP) in an EGFR biomarker-selected, previously untreated NSCLC population (2007) (1)
- Abstract 2761: Germline polymorphism discovered via a cell-based genome-wide approach predicts platinum response in ovarian and head and neck cancers (2010) (1)
- Profferred Paper Abstracts: Session C3: Combined Modality Therapy in NSCLC II: Wednesday, September 5: Combined Modality Therapy in NSCLC II, Wed, 10:30 - 12:15C3-01: Phase I Trial of Erlotinib-based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer (2007) (1)
- Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer. (1988) (1)
- Response to editorial by Harari and Fowler (1994) (1)
- De-escalation in HPV-negative locally advanced head and neck squamous cell cancer (LA-HNSCC) in patients after induction chemotherapy: A retrospective case series. (2018) (1)
- 342 A phase 1/2 study evaluating the safety, pharmacokinetics and efficacy of ABT-414 in subjects with advanced solid tumors likely to over-express the epidermal growth factor receptor (EGFR) (2014) (1)
- Updated Results From a Phase 1/Randomized Phase 2 Trial of Response-Adapted Volume De-escalation (RAVD) for Locally Advanced Head and Neck Cancer (2016) (1)
- Abstract 1625: Role of EphB4 in esophageal cancer: Expression, amplification, and therapeutic inhibition (2011) (1)
- An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC). (2018) (1)
- Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma (2022) (1)
- E-64. Bcl-2 as a target in lung cancer (2003) (1)
- 5507 ORAL A phase 2 study of axitinib (AG-013736; AG) in patients (pts) with advanced thyroid cancers (2007) (1)
- A phase I/II study of induction irinotecan (I), paclitaxel (P), and carboplatin (C) followed by concurrent thoracic (TXT) radiotherapy with irinotecan, paclitaxel, and carboplatin in unresectable, locally advanced non-small cell lung cancer (NSCLC) (2000) (1)
- The impact of induction chemotherapy on subsequent concurrent chemoradiotherapy (CRT) related side effects, function & quality of life (QOL) in head and neck cancer (HNC) (2004) (1)
- A Phase II Study of Erlotinib and Bevacizumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (2009) (1)
- Palbociclib: a new partner for cetuximab? (2019) (1)
- A Randomized Multi-Institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. (2022) (1)
- Induction chemotherapy (ind CT) followed by concomitant chemoradiotherapy (CXRT) for stage III non-small cell lung cancer (1998) (1)
- A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. (1995) (1)
- Correlation of homologous recombination deficiency in head and neck cancer with sensitivity to PARP inhibition. (2014) (0)
- D5-01: Prognostic significance of molecular markers and clinical factors in stage ib non-small cell lung cancer (NSCLC): a laboratory companion study to CALGB 9633 (2007) (0)
- Concomitant I nfusional P aclitaxel a nd F luorouracil, O ral Hydroxyurea, a nd H yperfractionate d R adiation f or L ocally Advanced S quamous H ead a nd N eck C ancer (2001) (0)
- 327 Phase II Study of Cetuximab and Lenalidomide in Recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck (2012) (0)
- Omission of the Pathologic Node-Negative Neck From Postoperative Radiation Therapy for Oral Cavity Cancer (2022) (0)
- Commentary (Brockstein/Vokes): Revisiting Induction Chemotherapy for Head and Neck Cancer (2005) (0)
- Randomized Phase II Study of Paclitaxel ( 1-Hour Infusion ) , Fluorouracil , Hydroxyurea , and Concomitant Twice Daily Radiation with or without Erythropoietin for Advanced Head and Neck Cancer (2003) (0)
- 166 A phase II study of CI-980 in advanced non small cell lung cancer (NSCLC) (1997) (0)
- Approach to & Management of Recurrent Head & Neck Cancer (2016) (0)
- Survival Analysis of Multi-Center Clinical Trial Using Endoscopy (END) and Endoscopic Ultrasound (EUS) Guided Fine Needle Injection (FNI) of Anti-Tumor Agent (TNFerade™ Biologic) in Patients with Locally Advanced Esophageal Cancer: 69 (2008) (0)
- Phase II randomized study of dose-dense docetaxel (Doc) and cisplatin (Cis) every two weeks with pegfilgrastim (Pfil) and darbepoetin alfa (Darb) with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (NSCLC): CAL (2016) (0)
- MA 03.09 The Cost and the Benefit: Front-Line Immunotherapy for Non-Small Cell Lung Cancer (2017) (0)
- Prognostic factors for clinical benefit after epidermal growth factor receptor (EGFR) directed therapy in squamous cell carcinomas of the head and neck (SCCHN) (2007) (0)
- Pharmacokinetic‐pharmacodynamic (PK‐PD) analysis of intestinal toxicity associated with irinotecan (CPT‐11): validation of biliary index (BI) (1996) (0)
- Dose intense re-irradiation and chemotherapy for recurrent head and neck squamous cell carcinoma (2004) (0)
- Exploratory analysis of clinical and translational factors associated with the inflamed phenotype in HNSCC. (2015) (0)
- Organ Preservation With Definitive Chemoradiotherapy for T4 Laryngeal Squamous Cell Carcinoma. (2021) (0)
- Investigation chemotherapy in multimodality therapy of non-small cell lung cancer. (1992) (0)
- Adjuvant treatment for high‐risk salivary gland malignancies and prognostic stratification based on a 20‐year single institution experience (2020) (0)
- Phase I/II study of a novel MDM-2 inhibitor (APG-115) in TP53 wild type salivary gland cancers (2022) (0)
- P2.04-12 Ph I Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and SBRT to Multiple Sites in Patients with Stage IV NSCLC (2019) (0)
- A phase I study of induction chemotherapy (CT) and concomitant chemoradiotherapy (CRT) with carboplatin (C), paclitaxel (P), and irinotecan (I) for stage III non-small cell lung cancer (NSCLC). (2004) (0)
- Performance and side effect evaluation of sequentially reduced radiotherapy doses in a phase II trial of induction chemotherapy (IndCT) followed by concomitant chemoradiotherapy (CTX) for advanced head and neck cancer (HNC). (2006) (0)
- Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries (2010) (0)
- Abstract 4919: Pathway profiling of head and neck cancer cell lines (2012) (0)
- Response-Adapted Volume De-escalation (RAVD) in Locally Advanced Head and Neck Cancer: Toxicity and Quality of Life Analyses (2016) (0)
- A phase-ii trial of neoadjuvant chemotherapy and concomitant chemoradiotherapy for the treatment of locally advanced nonsmall cell lung-cancer. (1994) (0)
- Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment (2022) (0)
- O-307 A two-arm phase I study of OSI-774 in combination with chemoradiation for patients with unresectable, locally advanced non-small cell lung cancer (2003) (0)
- Abstract 2746: An evaluation of poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer (2014) (0)
- Phase I I T rial o f I ntratumoral A dministration o f O NYX- 015, a R eplication-Sele ctive A denovirus, i n P atients W ith Refractory H ead a nd N eck C ancer (2001) (0)
- Abstract 4707: Validation of survival prognostic models for non-small-cell lung cancer instage- and age-specific groups. (2013) (0)
- P24.04 Concordance of Tissue and Cell-Free DNA-Based Next-Generation Sequencing in Patients With Lung Adenocarcinoma (2021) (0)
- 147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer (2022) (0)
- Genetic alterations in esophageal cancers: Detection by next-generation sequencing and potential for therapeutic targets. (2014) (0)
- Toxicity and Efficacy of Stereotactic Body Radiotherapy plus Nivolumab with Urelumab or Cabiralizumab in Patients with Advanced Solid Tumors (2020) (0)
- Characterisation of Potential Predictive Biomarkers of Response to Nivolumab in Checkmate 141 in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) (2017) (0)
- "Timing is Everything": the evolving role of immune checkpoint inhibition in nasopharyngeal carcinoma. (2023) (0)
- JS3 Keynotespeech THE ROLE OF ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES IN HEAD AND NECK CANCER (2012) (0)
- Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma (2022) (0)
- Considerations for the combined use of chemotherapy and radiation therapy. (1995) (0)
- P3.17-12 Phase II Trial of Atezolizumab Before and After Chemoradiation for Unresectable Stage III NSCLC (AFT-16): Trial in Progress (2018) (0)
- Concomitant Cisplatin, Vinorelbine, and Radiation in Advanced Chest Malignancies (1997) (0)
- E07-03: Treatment of locally advanced non-small cell lung cancer - neoadjuvant or adjuvant chemotherapy (2007) (0)
- 167 Phase I study of docetaxel (DOC) and comitant radiation therapy (RT) for advanced chest malignancies (1997) (0)
- The Receptor Tyrosine Kinase c-MET as a Novel Therapeutic Target in Head and Neck Cancer (2007) (0)
- Cell-Free HPV DNA Kinetics Predicted by Radiographic Response in Locoregional Viral-Associated Oropharyngeal Cancer Receiving Response-Adaptive Treatment – Exploratory Analysis of a Prospective Trial (2022) (0)
- Combining radiotherapy with systemic therapies. (2008) (0)
- Association of DRB1 and DRBQ haplotype 04:01~03:01 with HPV positive head and neck squamous cell carcinoma. (2017) (0)
- Combined Modality Strategies in the Treatment of Head and Neck Cancer (2003) (0)
- 78PComparison of chemoradiotherapy treatment strategies in stage III non-small cell lung cancer among elderly patients from multiple data sources (2017) (0)
- Organ Preservation with Definitive Chemoradiotherapy for T4 Laryngeal Squamous Cell Carcinoma (2022) (0)
- Definitive Chemoradiation Therapy for Advanced Oral Cavity Cancer: A 20-Year Experience (2016) (0)
- Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial (2008) (0)
- Human Papillomavirus Expression and p53 Accumulation in Squamous Cell Carcinoma of the Oral Cavity and Tonsil (1995) (0)
- 2022 Presidential Address: Advancing Equitable Cancer Care Through Innovation. (2022) (0)
- How D o H ead a nd N eck C ancer P atients P rioritize Treatment O utcomes B efore I nitiating T reatment (2000) (0)
- Cisplatin, 5-Fluorouracil and high dose oral Leucovorin (PFL) with Methotrexate and Piritrexim as Neo-Adjuvant chemotherapy for head and neck cancer (1991) (0)
- New reporting items and recommendations for randomized trials impacted by COVID-19 and force majeure events: a targeted approach (2022) (0)
- How Do I Treat a Patient with Newly Diagnosed Head and Neck Cancer (2011) (0)
- Phase II Tria l o f Intratumoral Adminis trat ion of ONYX-015 , a Repl icat ion-Select i ve Adenovirus , in Pat ients With Refractory Head and Neck Cancer (2000) (0)
- P79.06 CHIO3: ChEmotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer (AFT-46) (2021) (0)
- Revisiting induction chemotherapy for head and neck cancer - References and reviews: Commentary (2005) (0)
- 255 Transcriptome sequencing of upper aerodigestive tract cancer cell lines to reveal potential therapeutic targets (2010) (0)
- Differences in clinical trial patient attributes and outcomes according to trial enrollment setting: analyses from 10 CALGB lung cancer trials (2008) (0)
- Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. (2010) (0)
- 5 A phase II study of 9-aminocamptothecin (9-AC) in patients (pts) with non small cell lung cancer (NSCLC) (1997) (0)
- Abstract A37: Interim analysis of CALGB 150607: A pilot study of the mutational & expression status of MET, HGF, EGFR, KRAS, p53, c-CBL, and E-cadherin in resected lung adenocarcinoma specimens (2012) (0)
- Oral Cancer in the Non-Smoker, Non-Drinker Population - Is Dental Hardware a Possible Risk Factor? (2018) (0)
- Small Molecule Therapeutics Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer (2014) (0)
- RATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC). (2019) (0)
- OC-0492: A pooled analysis of radiotherapy dose & targeting strategies for stage 3 non-small cell lung cancer (2018) (0)
- Abstract 963: Screening of neoantigen-specific T cells in head and neck cancer and establishment of T-cell receptor-engineered T cells with cytotoxic reactivity (2018) (0)
- Factors Associated with Non-cancer Mortality in Advanced Head and Neck Cancer: A Competing Risks Analysis (2008) (0)
- RO01.01 Prospective Evaluation of Ipilimumab and Nivolumab in Patients with Non-Small Cell Lung Cancer Brain Metastasis (2021) (0)
- Original article A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer (2005) (0)
- Commentary on “Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Non–Small-Cell Lung Cancer” (2000) (0)
- Ifosfamide-based three-drug combinations in non-small cell lung cancer (1997) (0)
- Abstract 2341: Functional analysis of paxillin mutations identified in lung cancer and malignant mesothelioma: Implications for cell migration/motility (2011) (0)
- 273 A phase I study of concomitant chemoradiotherapy with cisplatin (CDDP) and vinorelbine (NVB) for advanced malignancies of the chest (1997) (0)
- An A ttenuated A denovirus, O NYX-015, A s M outhwash T herapy for P remalignant O ral D ysplasia (2006) (0)
- Crizotinib: ALK/Met inhibitor, oncolytic (2011) (0)
- Update in head and neck oncology. (2004) (0)
- Flavopiridol, A N ovel C yclin-Dependent K inase I nhibitor, in M etastatic R enal C ancer: A U niversity o f C hicago P hase II C onsortium S tudy (2000) (0)
- Evaluation of Initial Metastatic Tumor Location and Radiation Response to Determine Outcomes in Patients Who Received Combination Stereotactic Body Radiotherapy and Immunotherapy for NSCLC. (2021) (0)
- Pathologic Predictors for Outcome in Recurrent and Second Primary Head and Neck Cancer Patients Undergoing Surgery followed by Concurrent Chemo-reirradiation (2008) (0)
- JS3. the role of molecular-targeting therapy in radiotherapy (2012) (0)
- A phase I study of G3139 in combination with RICE chemotherapy in relapsed non-Hodgkin's lymphoma (NHL). (2006) (0)
- Prognostic factors in early stage head and neck squamous cell carcinoma (HNSCC) patients in a prospective clinical trial. (2004) (0)
- IS8. head and neck cancer (2012) (0)
- Main Session II Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer (2001) (0)
- P-3 A phase II trial of the combination of temozolomide and irinotecan as second-line therapy for patients with non-small cell lung cancer (2003) (0)
- Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2). (1996) (0)
- Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival in Classic Papers and Current Comments, Head and Neck Cancer Research (1999) (0)
- Dysphagia and Aspiration After Chemoradiation Therapy for Locoregionally-Advanced Head-and-Neck Cancer: A Prospective Study of the Dose–Effect Relationship in Accelerated Fractionation by Concomitant Boost With Cisplatin and Cetuximab From the EPIC Trial (2014) (0)
- Abstract C166: Phase II study of cetuximab and lenalidomide in recurrent/metastatic squamous cell carcinoma of the head and neck. (2013) (0)
- 6551 POSTER Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial (2007) (0)
- Adjuvant Radiation and Chemoradiation for High-Risk Salivary Gland Malignancies: A 20-Year Single Institution Experience (2019) (0)
- Annual Meeting Exhibits (1989) (0)
- MA06.10 A Pooled Analysis Comparing the Outcomes of Elderly to Younger Patients on NCTN Trials of Concurrent CCRT for Stage 3 NSCLC (2017) (0)
- 507 Evaluation of patients with progressive metastatic head and neck cancer treated with PD-1 inhibition with Pembrolizumab and radiation therapy: Assessment of local and systemic effects (2015) (0)
- Combined modality therapy for stage III non-small cell lung cancer : the University of Chicago experience (1991) (0)
- The importance of quality-of-life measurements in oncology. (2002) (0)
- Radiation Therapy Oncology Group. Research Plan 2002-2006. Medical Oncology Committee. (2001) (0)
- Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC (2021) (0)
- Phase I and pharmacokinetic (PK) study of PTK787/ZK222584 (PTK/ZK) plus capecitabine (cape) in patients (Pts) with advanced cancer (2007) (0)
- Validation of the CALGB and EORTC Prognostic Models for Mesothelioma based on multiple CALGB Trials (Alliance) (2013) (0)
- Welcome to the Chicago Multidisciplinary Symposium in Thoracic Oncology (2010) (0)
- Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL (2017) (0)
- MS 11.05 Definitive Chemoradiotherapy in Superior Sulcus Tumor (2017) (0)
- P01.23 Veliparib (V) in Combination with Carboplatin/Paclitaxel (C/P)-Based Chemoradiotherapy (CRT) in Patients With Stage III NSCLC (2021) (0)
- Concomitant chemoradiotherapy with Cisplatin dose escalation as palliative therapy for advanced malignancies of the chest (1994) (0)
- Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09). (2019) (0)
- Esophageal cancer therapy: a decade of inertia. (2001) (0)
- 130 POSTER Phase II trial of Sequenced Bevacizumab and Erlotinib with Bevacizumab and Chemotherapy for 1st Line Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) (2006) (0)
- Combination regimens and dose intensification in non-small cell lung cancer: a panel discussion (Part 1). (1996) (0)
- Mature Outcomes of 61.2 Gy Concomitant Boost (CB) Thoracic Radiotherapy (TRT) in Limited Stage Small Cell Lung Cancer (LSCLC): CALGB 30610 (Alliance) / RTOG 0538. (2021) (0)
- Phase I I T rial o f Z D1839 i n R ecurrent o r M etastatic S quamous Cell C arcinoma o f t he H ead a nd N eck (2003) (0)
- Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E). (2009) (0)
- A Global Approach to Cancer Equity in the Hispanic/Latinx Population. (2022) (0)
- AB012. Automated histologic subtyping of thymic epithelial tumors with deep learning (2022) (0)
- 2117 Organ preservation in stage II and III head and neck cancer utilizing alternate week concomitant chemoradiotherapy (1996) (0)
- Optimization of Combined Modality Therapy for Locoregionally Advanced Head and Neck Cancer (2012) (0)
- Abstract 101: WHSC1L1 as a therapeutic target in squamous cell carcinoma of the head and neck (2015) (0)
- Reply to s. Chakraborty et al. (2015) (0)
- Comparison of two large, genetically and clinically annotated head and neck cancer (HNC) cohorts (TCGA, CHGC) and differential treatment effects on TP53 mutated, as well as oral cavity cancers. (2015) (0)
- Routine versus clinically indicated post-treatment surveillance in head and neck cancer. (2010) (0)
- An Attenuated Adenovirus , ONYX-015 , As Mouthwash Therapy for Premal ignant (2003) (0)
- Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Base of Tongue Cancer (2007) (0)
- P-473 Phase II trial of temozolomide and innotecan as second-linetreatment for advance non-small cell lung cancer (2005) (0)
- Recurrent or metastatic head and neck squamous cell carcinoma that is not responsive to platinum-based chemotherapy progresses very rapidly , and patients have a very poor prognosis , ” (2016) (0)
- S037 Advanced T Stage Is Associated With Improved Swallowing Following Concurrent Chemoradiotherapy in Head and Neck Cancer Patients (2006) (0)
- Impact of Induction Chemotherapy on Treatment Outcomes in Locoregionally Advanced Head and Neck Carcinoma Patients Treated with Concurrent Chemotherapy and Hyperfractionated Radiotherapy (2010) (0)
- Expression of protein kinase C beta (PKCß) as a prognostic marker in non-small cell lung cancer (NSCLC) and mesothelioma (2007) (0)
- Association of low serum albumin concentration with reduced overall survival for patients with metastatic head and neck cancer receiving anti-programmed death receptor-1 therapy. (2018) (0)
- Phase II Trial of Gefitinib 250 mgDaily in Patientswith Recurrent and / orMetastatic Squamous Cell Carcinoma of the Head and Neck (2005) (0)
- Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance). (2017) (0)
- Use of DNA repair pathway analysis to predict overall survival in head and neck cancer patients treated with TFHX chemoradiotherapy. (2009) (0)
- DOUBLETS AND TRIPLETS : NEW DRUG COMBINATIONS IN THE PALLIATIVE CARE OF NSCLC (1997) (0)
- Characterizing Lymph Node Burden With Elective Unilateral Neck Irradiation in Human Papillomavirus-Positive Tonsil Squamous Cell Carcinoma: Defining the Upper Limits (2022) (0)
- Abstract LB-398: Detection of copy number alterations in 124 head and neck squamous cell carcinomas using the Nanostring nCounter assay (2012) (0)
- 1546P Impact of stratification factors on outcomes in limited-stage small cell lung cancer: Analysis of CALGB 30610 (Alliance)/RTOG 0538 (2022) (0)
- Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. (2023) (0)
- Intensive induction chemotherapy followed by concomitant chemoradiotherapy in the management of locoregionally advanced carcinoma of the pyriform sinus. (2003) (0)
- Pharmacokinetics and pharmacodynamics of anti-cancer drug losoxantrone when given in combination with cyclophosphamide (1996) (0)
- Umbrella Test the effect of one or more drugs on one or more single mutations in a variety of cancer types Test the impact of different drugs on different mutations in a single type of cancer Basket (2015) (0)
- On the design, conduct and lessons learned from Lung-MAP (SWOGS1400): A biomarker-driven master protocol to evaluate biomarker-driventherapies for previously-treated squamous lung cancer (2021) (0)
- Induction of Inflammatory Macrophages in Solid Tumors by All-trans Retinoic Acid Augments Radiation Efficacy (2022) (0)
- The impact of staging by positron emission tomography (PET) on overall survival (OS) and progression-free survival (PFS) in the phase III PROCLAIM study (2016) (0)
- Safety and Efficacy of Multi-site Stereotactic Body Radiotherapy and Pembrolizumab for Patients with Large, Treatment-refractory Tumors (2020) (0)
- STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. (2023) (0)
- Previous Chemoradiotherapy Predicts for Worse Survival in Patients Undergoing Chemo-reirradiation for Recurrent and Second Primary Head and Neck Cancer (2008) (0)
- Abstract LB-239: Inhibition of MET/RON in lung cancer (2014) (0)
- Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer (NSCLC). (2016) (0)
- PS04.08 A Phase I Trial to Evaluate Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Stage IV NSCLC: Topic: Medical Oncology (2017) (0)
- Efficacy of concomitant chemoradiotherapy in poor prognosis head and neck cancer (1991) (0)
- Mathematical predication models to optimize post-treatment surveillance in HPV-associated oropharyngeal cancer. (2021) (0)
- 2425: Induction Chemotherapy followed by Chemoradiotherapy in the Treatment of Locally Advanced Tonsillar Squamous Cell Carcinoma (2006) (0)
- Effects of vascular endothelial growth factor (VEGF) signaling inhibition on human erythropoiesis. (2009) (0)
- Assessment of Tumor Burden and Response by RECIST vs. Volume Change in HPV+ Oropharyngeal Cancer – An Exploratory Analysis of Prospective Trials (2022) (0)
- Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer. (2023) (0)
- Data modifications to phase I study of suramin. (1996) (0)
- Beyond PACIFIC: Uncharted Waters. (2021) (0)
- Reply to the Letter by Robins et al. (2006) (0)
- Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction (1995) (0)
- The standard to come: systemic therapies for systemic disease. (1995) (0)
- Characterization of the T-cell receptor repertoire and immune microenvironment in patients with locoregionally advanced squamous cell carcinoma of the head and neck. (2017) (0)
- Treatment of advanced head and neck cancer: Past, present, and future (2008) (0)
- P-533 Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (2003) (0)
- Primary and Metastatic Brain Tumors (2003) (0)
- A phase I cohort study of suramin in patients with advanced cancer (1992) (0)
- P2.14-12 Tyrosine Kinase Inhibitor Resistance Mechanisms in EGFR T790M-Positive Lung Cancer: The University of Chicago Experience (2019) (0)
- Feasibility Of Next-Generation Genomic Sequencing To Identify Prognostic Biomarkers Of Chemoradiation Response For Salivary Gland Malignancies (2020) (0)
- Abstract A207: Whole transcriptome profiling in upper aerodigestive tract cancers (2009) (0)
- Y1-14: Hurdles in the Development of a New Drug (2007) (0)
- P2.03a-055 Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Lung Patients: A Pooled Analysis of US Cooperative Group Trials: Topic: Clinical Trials (2017) (0)
- Welcome by the Meeting Chair and Program Committee Chair (2008) (0)
- Is This the Dawn of Precision Oncology in Head and Neck Cancer? (2021) (0)
- Efforts in Lung Cancer : Focus on Early-Stage Non – Small-Cell Lung Cancer comprehensive review (2011) (0)
- Absolute lymphocyte count (ALC) during and after chemoradiation (CRT) for squamous cell carcinoma of the head and neck (SCCHN): Effect of the regimen and potential therapeutic implications. (2018) (0)
- Radiation Dose and Volume De-Escalation for High-Risk HPV Positive Oropharyngeal Cancer (2022) (0)
- Does chemotherapy for head and neck cancer improve symptoms? (1997) (0)
- ED10.04 New Developments for Systemic Therapies in Stage III NSCLC (2017) (0)
- Abstract 1861: EPHB4 as a potential therapeutic target for esophageal cancer (2012) (0)
- Ifosfamide-based three-drug combination regimens in non-small cell lung cancer. (1998) (0)
- MA 18.06 Clinical Prognostic Model for Older Patients with Advanced Non-Small Cell Lung Cancer (2017) (0)
- Steering Committee Members (2008) (0)
- P2-124: Focal adhesion paxillin induces nodular cell growth, invasion, and angiogenesis in lung cancer (2007) (0)
- Predictive markers of response in a Phase I/II pharmacodynamic (PD) study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC) (2007) (0)
- Phase II trial of O6-benzylguanine (O6BG) and BCNU in patients with advanced melanoma. (2004) (0)
- Response-Adapted Volume De-escalation (RAVD) in Human Papillomavirus-Positive Oropharyngeal Squamous Cell Cancer (OPX SCC) (2015) (0)
- Mandibular Osteoradionecrosis After Chemoradiation Therapy for Locoregionally Advanced Head-and-Neck Cancer: A Prospective Study of the Dose–Effect Relationship in Accelerated Fractionation by Concomitant Boost With Cisplatin and Cetuximab From the EPIC Trial : Definitive Management of Head-and-Neck (2014) (0)
- P3-087: Phase II trial of sequenced bevacizumab and erlotinib with bevacizumab and chemotherapy for 1st line stage IIIB or IV Non-small cell lung cancer (NSCLC) (2007) (0)
- P3-133: Bortezomib for advanced Bronchioloalveolar Carcinoma (BAC): a California–Pittsburgh Cancer Consortium multicenter phase II study (2007) (0)
- Randomized comparison of neoadjuvant cisplatin and fluorouracil infustion followed by radiation versus concomitant treatment in advanced head and neck cancer. In Class Papers and Current Comments, Head and Neck Cancer Research (1999) (0)
- 867P A phase I trial of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma (2021) (0)
- S115 The Receptor Tyrosine Kinase c-MET Is Mutated in Head and Neck Cancer and Is a Promising Novel Target (2006) (0)
- Screening of neoantigen-specific T cells and establishment of T-cell receptor-engineered T cells: Implications for head and neck squamous carcinoma. (2018) (0)
- Progress in unresectable stage III non-small cell lung cancer. (1996) (0)
- Phase I I S tudy o f t he F arnesyl T ransferase I nhibitor R 115777 in P atients W ith A dvanced N on-Small-Cell L ung C ancer (2003) (0)
- Activity o f D ocetaxel i n P latinum-Treated N on-Small-Cell Lung C ancer: R esults o f a P hase I I M ulticenter T rial (2000) (0)
- Commentary (Cohen/Vokes): Gene Therapy for Head and Neck Cancers (2001) (0)
- Dose and Volume De-Escalation for HPV-Positive Oropharyngeal Cancer is Associated with Favorable Post-Treatment Functional Outcomes (2019) (0)
- Immune subgroups and the tumor microenvironment as a potential new biomarker to assess response to immunotherapy. (2019) (0)
- Abstract A085: Racial differences in organ preservation with definitive chemoradiotherapy among patients with T4 laryngeal squamous cell carcinoma (2023) (0)
- Complete Radiographic Response Correlates With Pathologic Complete Response in Locoregionally Advanced Head and Neck Cancer (2015) (0)
- P14.27 Pathogenic Genomic Alterations of CDKN2A Predict Immunotherapy Resistance in NSCLC (2021) (0)
This paper list is powered by the following services:
Other Resources About Everett E. Vokes
What Schools Are Affiliated With Everett E. Vokes?
Everett E. Vokes is affiliated with the following schools:
